Martijn Zwinderman

Mr. Martijn Zwinderman


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2018 in Molecules
Verified
Journal Article
Open access
PDF file
FCFangyuan Cao
Fangyuan Cao
MZMartijn Zwinderman
Martijn Zwinderman
Frank DekkerFrank Dekker
Frank Dekker
Histone deacetylases (HDACs) are epigenetic drug targets that have gained major scientific attention. Inhibition of these important regulatory enzymes is used to treat cancer, and has the potential to treat a host of other diseases. However, currently marketed HDAC inhibitors lack selectivity for the various HDAC isoenzymes. Several studies have shown that HDAC3, in particular, plays an important role in inflammation and degenerative neurological diseases, but the development of selective HDAC3 inhibitors has been challenging. This review provides an up-to-date overview of selective HDAC3 inhibitors, and aims to support the development of novel HDAC3 inhibitors in the future.

7 September 2019 in Epigenomes
Verified
Journal Article
Open access
PDF file
MZMartijn Zwinderman
Martijn Zwinderman
SWSander de Weerd
Sander de Weerd
Frank DekkerFrank Dekker
Frank Dekker
Around three million patients die due to airway inflammatory diseases each year. The most notable of these diseases are asthma and chronic obstructive pulmonary disease (COPD). Therefore, new therapies are urgently needed. Promising targets are histone deacetylases (HDACs), since they regulate posttranslational protein acetylation. Over a thousand proteins are reversibly acetylated, and acetylation critically influences aberrant intracellular signaling pathways in asthma and COPD. The diverse set of selective and non-selective HDAC inhibitors used in pre-clinical models of airway inflammation show promising results, but several challenges still need to be overcome. One such challenge is the design of HDAC inhibitors with unique selectivity profiles, such as selectivity towards specific HDAC complexes. Novel strategies to disrupt HDAC complexes should be developed to validate HDACs further as targets for new anti-inflammatory pulmonary treatments.

1 January 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MWMagdalena Wójcik
Magdalena Wójcik
NENikolaos Eleftheriadis
Nikolaos Eleftheriadis
MZMartijn Zwinderman
Martijn Zwinderman
ADAlexander Dömling
Alexander Dömling
Frank DekkerFrank Dekker
Frank Dekker
YBYkelien L. Boersma
Ykelien L. Boersma